These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27587584)

  • 1. Structures of mithramycin analogues bound to DNA and implications for targeting transcription factor FLI1.
    Hou C; Weidenbach S; Cano KE; Wang Z; Mitra P; Ivanov DN; Rohr J; Tsodikov OV
    Nucleic Acids Res; 2016 Oct; 44(18):8990-9004. PubMed ID: 27587584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric interference in oncogenic FLI1 and ERG transactions by mithramycins.
    Hou C; Mandal A; Rohr J; Tsodikov OV
    Structure; 2021 May; 29(5):404-412.e4. PubMed ID: 33275876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solution structure of mithramycin dimers bound to partially overlapping sites on DNA.
    Sastry M; Fiala R; Patel DJ
    J Mol Biol; 1995 Sep; 251(5):674-89. PubMed ID: 7666419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimerization and DNA recognition rules of mithramycin and its analogues.
    Weidenbach S; Hou C; Chen JM; Tsodikov OV; Rohr J
    J Inorg Biochem; 2016 Mar; 156():40-7. PubMed ID: 26760230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Basis for Dimerization and DNA Binding of Transcription Factor FLI1.
    Hou C; Tsodikov OV
    Biochemistry; 2015 Dec; 54(50):7365-74. PubMed ID: 26618620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FLI1 and EWS-FLI1 function as ternary complex factors and ELK1 and SAP1a function as ternary and quaternary complex factors on the Egr1 promoter serum response elements.
    Watson DK; Robinson L; Hodge DR; Kola I; Papas TS; Seth A
    Oncogene; 1997 Jan; 14(2):213-21. PubMed ID: 9010223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cooperative DNA binding with AP-1 proteins is required for transformation by EWS-Ets fusion proteins.
    Kim S; Denny CT; Wisdom R
    Mol Cell Biol; 2006 Apr; 26(7):2467-78. PubMed ID: 16537893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript.
    Grohar PJ; Glod J; Peer CJ; Sissung TM; Arnaldez FI; Long L; Figg WD; Whitcomb P; Helman LJ; Widemann BC
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):645-652. PubMed ID: 28735378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A polypeptide from the junction region sequence of EWS-FLI1 inhibits Ewing's sarcoma cells, interacts with the EWS-FLI1 and partner proteins.
    Thangaretnam KP; Gopisetty G; Ramanathan P; Rajkumar T
    Sci Rep; 2017 Aug; 7(1):7172. PubMed ID: 28775288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-chain antibodies to the EWS NH(2) terminus structurally discriminate between intact and chimeric EWS in Ewing's sarcoma and interfere with the transcriptional activity of EWS in vivo.
    Aryee DN; Kreppel M; Bachmaier R; Uren A; Muehlbacher K; Wagner S; Breiteneder H; Ban J; Toretsky JA; Kovar H
    Cancer Res; 2006 Oct; 66(20):9862-9. PubMed ID: 17047047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA helicase A activity is inhibited by oncogenic transcription factor EWS-FLI1.
    Erkizan HV; Schneider JA; Sajwan K; Graham GT; Griffin B; Chasovskikh S; Youbi SE; Kallarakal A; Chruszcz M; Padmanabhan R; Casey JL; Üren A; Toretsky JA
    Nucleic Acids Res; 2015 Jan; 43(2):1069-80. PubMed ID: 25564528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing.
    Selvanathan SP; Graham GT; Erkizan HV; Dirksen U; Natarajan TG; Dakic A; Yu S; Liu X; Paulsen MT; Ljungman ME; Wu CH; Lawlor ER; Üren A; Toretsky JA
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1307-16. PubMed ID: 25737553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mithramycin 2'-Oximes with Improved Selectivity, Pharmacokinetics, and Ewing Sarcoma Antitumor Efficacy.
    Liu Y; Eckenrode JM; Zhang Y; Zhang J; Hayden RC; Kyomuhangi A; Ponomareva LV; Cui Z; Rohr J; Tsodikov OV; Van Lanen SG; Shaaban KA; Leggas M; Thorson JS
    J Med Chem; 2020 Nov; 63(22):14067-14086. PubMed ID: 33191745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target.
    Remsing LL; Bahadori HR; Carbone GM; McGuffie EM; Catapano CV; Rohr J
    Biochemistry; 2003 Jul; 42(27):8313-24. PubMed ID: 12846580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis of DNA recognition by anticancer antibiotics, chromomycin A(3), and mithramycin: roles of minor groove width and ligand flexibility.
    Chakrabarti S; Bhattacharyya D; Dasgupta D
    Biopolymers; 2000-2001; 56(2):85-95. PubMed ID: 11592055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
    Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
    Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma.
    Tosso PN; Kong Y; Scher L; Cummins R; Schneider J; Rahim S; Holman KT; Toretsky J; Wang K; Üren A; Brown ML
    J Med Chem; 2014 Dec; 57(24):10290-303. PubMed ID: 25432018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How mithramycin stereochemistry dictates its structure and DNA binding function.
    Hou C; Rohr J; Parkin S; Tsodikov OV
    Medchemcomm; 2019 May; 10(5):735-741. PubMed ID: 31191864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy.
    Albertini V; Jain A; Vignati S; Napoli S; Rinaldi A; Kwee I; Nur-e-Alam M; Bergant J; Bertoni F; Carbone GM; Rohr J; Catapano CV
    Nucleic Acids Res; 2006; 34(6):1721-34. PubMed ID: 16571899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solution structure of the mithramycin dimer-DNA complex.
    Sastry M; Patel DJ
    Biochemistry; 1993 Jul; 32(26):6588-604. PubMed ID: 8329387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.